Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics.
about
Tankyrase-1 assembly to large protein complexes blocks its telomeric functionDisruption of Wnt/β-Catenin Signaling and Telomeric Shortening Are Inextricable Consequences of Tankyrase Inhibition in Human CellsTelomere and Telomerase Therapeutics in CancerTherapeutic targeting of replicative immortalityTelomerase inhibitor Imetelstat (GRN163L) limits the lifespan of human pancreatic cancer cellsB-aggressive lymphoma family proteins have unique domains that modulate transcription and exhibit poly(ADP-ribose) polymerase activity.TRF1 ensures the centromeric function of Aurora-B and proper chromosome segregation.Gene expression in nontumoral liver tissue and recurrence-free survival in hepatitis C virus-positive hepatocellular carcinomaInhibition of poly (ADP-Ribose) polymerase-1 in telomerase deficient mouse embryonic fibroblasts increases arsenite-induced genome instabilityRegulatory roles of tankyrase 1 at telomeres and in DNA repair: suppression of T-SCE and stabilization of DNA-PKcs.What has senescence got to do with cancer?Tankyrase-1 function at telomeres and during mitosis is regulated by Polo-like kinase-1-mediated phosphorylation.Telomerase: a potential therapeutic target for cancer.Telomerase and its potential for therapeutic intervention.The telomeric PARP, tankyrases, as targets for cancer therapyPolyADP-ribosylation and cancer.Treatment of pediatric brain tumors.Rapid regulation of telomere length is mediated by poly(ADP-ribose) polymerase-1.Telomere length influences cancer cell differentiation in vivo.Mechanism of DNA damage responses induced by exposure to an oligonucleotide homologous to the telomere overhang in melanoma.The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance.Telomerase enzyme inhibition (TEI) and cytolytic therapy in the management of androgen independent osseous metastatic prostate cancerTargeting the telomere and shelterin complex for cancer therapy: current views and future perspectives.NAD+ metabolism and oxidative stress: the golden nucleotide on a crown of thorns.Tankyrases as drug targets.Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases.Treating Cancer by Targeting Telomeres and Telomerase.Inhibition of telomerase activity preferentially targets aldehyde dehydrogenase-positive cancer stem-like cells in lung cancer.Senescence from glioma stem cell differentiation promotes tumor growthAnti-TANKyrase weapons promote myelination.Multiscale in situ analysis of the role of dyskerin in lung cancer cells.Myocardial induction of nucleostemin in response to postnatal growth and pathological challenge.The role of the poly(ADP-ribose) polymerase tankyrase1 in telomere length control by the TRF1 component of the shelterin complex.Insulin-stimulated exocytosis of GLUT4 is enhanced by IRAP and its partner tankyrase.The role of telomere maintenance in the spontaneous growth arrest of pediatric low-grade gliomas.Inhibitors of telomerase and poly(ADP-ribose) polymerases synergize to limit the lifespan of pancreatic cancer cells.G-Quadruplex stabilization by telomestatin induces TRF2 protein dissociation from telomeres and anaphase bridge formation accompanied by loss of the 3' telomeric overhang in cancer cells.Whole proteome analysis of human tankyrase knockout cells reveals targets of tankyrase-mediated degradation.2-Phenylquinazolinones as dual-activity tankyrase-kinase inhibitors.Discovery of new dual binding TNKS inhibitors of Wnt signaling inhibition by pharmacophore modeling, molecular docking and bioassay.
P2860
Q24294752-DF09D2D1-4C23-4430-8ABE-AE0B2A4A7FF9Q24337325-EED3B333-C239-47C5-B55C-31B21BA385CFQ26744808-EF20D5F2-23BD-4C2C-BD40-92BC13888311Q27027457-5B1EA4A5-70A9-4B92-B7B0-C370093AAB60Q28538403-8096A1F5-3534-48D3-BF65-21BF62B1C390Q29977777-7F12049D-422D-4319-8A6B-AFD5E10B991EQ30580516-A5BAC52A-0A59-40AD-9F21-58DA4B79DFE9Q33797504-EB42FAE8-BED3-4898-AA7D-447037852BFCQ34009753-47D729B9-6184-46EF-B4CB-11657F18F6B2Q34361226-41A849EA-1C7E-4F43-ABE3-EA85E13874F7Q35585808-F1567273-D740-463D-BA8E-C21D7C0AFB29Q35687096-FC8FA46F-80F2-4E45-AD57-4E3CCD6C8ABCQ36158693-1EC2F396-9386-44EE-972A-66C5B10B8276Q36171337-06BB0D09-3A7B-4960-A0D2-BCE154F7ACD1Q36371977-8397F7FB-8580-4503-90C1-B128A0CF9631Q36889328-2A3168E7-FC23-4BBE-85E1-9442D29FA078Q36953476-DA94C409-9CAC-4A01-ACF1-159603EADAF1Q36959668-86EF9E2C-0E9E-4154-BB5C-5F9FC7BA0B1AQ37036345-BB50C715-B928-4B1A-BAF8-4E4DFA74CFFFQ37093551-EC4313E1-2AD6-43D4-914F-E3DC656C7D5DQ37317534-2A5EF24E-D1F6-447C-B4D9-ED24BC0BF250Q37542029-9A8B8C80-E165-4A29-B5C3-E0ACD8583167Q37825614-4E312BDC-1B85-4A54-81D3-8CFA54E8D223Q37984791-7E30AA1C-1977-40B3-A5D5-5AB701E3FBADQ38104494-7F458E38-2DCB-4A6C-9FA3-16895D7A2CC7Q38191981-C1CBA2B3-CD48-46BD-B989-EAF7B6F6928CQ38288984-6B37C2DE-EFC5-4ADF-8406-8C958E17F8D3Q38801841-D162C051-8A58-4FCA-A93D-9B7473A3B230Q38802705-75512375-2B2E-4F79-A0FE-2AE0CB3381EFQ39059942-AE144563-6CA9-4296-8897-EEFF794B74C5Q39227538-B4CA5BF1-3D26-4C22-89D9-E53A82A88B0DQ39976153-18886B16-D467-4494-852C-243B3097D0C0Q40121332-8482C4ED-A5C7-4595-8271-CB8ABE199C8FQ40216655-6051F268-2A79-4088-AC8A-8E2FAC3473E8Q43259828-C610F68C-3D9F-430C-9CBA-3889B32FE5C0Q46306025-B2AD8C35-1ED4-4B3A-8017-B35E2F7540BCQ46815329-13ADE30D-C724-4D6B-AC25-67E9E82FB8DDQ47103031-6811573B-6E3D-462F-8D94-CE4246BC658BQ48158007-3B36D53E-4413-4947-BFEE-BDA99A955821Q51071963-8EE36A0E-9097-45CF-8AF6-DB83F86BECF7
P2860
Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics.
@ast
Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics.
@en
Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics.
@nl
type
label
Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics.
@ast
Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics.
@en
Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics.
@nl
prefLabel
Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics.
@ast
Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics.
@en
Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics.
@nl
P1433
P1476
Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics
@en
P2093
Takashi Tsuruo
Yukiko Muramatsu
P356
10.1016/J.CCR.2004.11.021
P577
2005-01-01T00:00:00Z